Bristol-Myers Squibb Co. v. Superior Court

Vista Outdoor Announces General Counsel for Revelyst

Retrieved on: 
Monday, October 23, 2023
Legal, Other Retail, Other Manufacturing, Professional Services, Consumer, Other Consumer, Manufacturing, Retail, Vista Outdoor, Capital market, Bristol-Myers Squibb Co. v. Superior Court, NYSE, Boxed, Georgetown University, Corporation, Wardwell, Multimedia, Private practice, Yale University, Growth, CFO, Corporate group, Professional, Daisy Outdoor Products, General counsel, Bachelor of Arts

Vista Outdoor Inc. (NYSE: VSTO), the parent company of 41 renowned brands that design, manufacture and market sporting and outdoor lifestyle products to consumers around the globe, today announced that Jung Choi will serve as General Counsel and Corporate Secretary for Revelyst following Vista Outdoor’s planned separation of its Outdoor Products segment into a standalone public company .

Key Points: 
  • Vista Outdoor Inc. (NYSE: VSTO), the parent company of 41 renowned brands that design, manufacture and market sporting and outdoor lifestyle products to consumers around the globe, today announced that Jung Choi will serve as General Counsel and Corporate Secretary for Revelyst following Vista Outdoor’s planned separation of its Outdoor Products segment into a standalone public company .
  • Until the completion of the separation, Choi will serve as Co-General Counsel of Vista Outdoor, with responsibility for the Outdoor Products segment.
  • View the full release here: https://www.businesswire.com/news/home/20231023562177/en/
    Vista Outdoor Inc. today announced that Jung Choi will serve as General Counsel and Corporate Secretary for Revelyst following Vista Outdoor’s planned separation of its outdoor products segment into a standalone public company.
  • Until the completion of the separation, Choi will serve as Co-General Counsel of Vista Outdoor, with responsibility for the Outdoor Products segment.

Pennsylvania Superior Court Denies U.S. Steel Permission to Appeal Class Action for Over 123,000 Pennsylvania Residents, Announces Miner, Barnhill & Galland P.C.

Retrieved on: 
Tuesday, October 17, 2023
Class Action Lawsuit, Professional Services, Legal, Coke, Headache, Superior Court of Pennsylvania, Superior court, Nausea, Bristol-Myers Squibb Co. v. Superior Court, Miner, Air pollution, Steel, Tobacco, U.S. Steel

GD-19-005325), arose in December 2018 after a massive fire disabled U.S. Steel’s pollution controls at its coke works in Clairton, Pennsylvania.

Key Points: 
  • GD-19-005325), arose in December 2018 after a massive fire disabled U.S. Steel’s pollution controls at its coke works in Clairton, Pennsylvania.
  • By denying U.S. Steel permission to appeal, Monday’s ruling allows the representative plaintiffs to move forward to seek damages for more than 123,000 residents of the 22 communities.
  • “We’re glad the Superior Court decided to reject U.S. Steel’s meritless appeal,” said Sarah Siskind, lead attorney for the plaintiffs and a partner at Miner, Barnhill & Galland, P.C.
  • Residents can call or text (412) 545-3473, or sign up for case updates using the contact form on the following webpage: www.MonValleyPollution.com .

Global Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems Analysis Report 2023-2028 Featuring Major Players - Bristol-Myers Squibb, Camurus, GlaxoSmithKline, Merck & Novartis

Retrieved on: 
Thursday, June 29, 2023
Nanoparticle, GSK plc, Drug development, Face, Administration, COVID-19, Clinical trial, Quality of life, Lonrho, Research, Forecasting, Patent, Patient, Bristol-Myers Squibb Co. v. Superior Court, Ecosystem, Health, Environment, Nanotechnology, Novartis, Fine chemical, Pharmaceutical industry, Medical imaging, Biotechnology, Camurus

DUBLIN, June 29, 2023 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 29, 2023 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.
  • The most rapid advances have been made in the application of nanoparticles in drug research and development, drug formulation, and the development of novel drug delivery systems using nanoparticle carriers.
  • The size and shape of nanoparticles is an important aspect to determine their properties and influences the drug performance and efficacy on the body.
  • Drug formulation and drug delivery systems are major application areas that are lucrative for startups in Europe, thus contributing to the market's growth.

Global Non-Hodgkin Lymphoma Therapeutics Market to Grow by $5.42 Billion During 2023-2027: - ResearchAndMarkets.com

Retrieved on: 
Friday, February 24, 2023
Pharmaceutical, Health, Oncology, Baxter International, Merck Group, Non-Hodgkin lymphoma, Cancer, Novartis, Eastman Kodak Co. v. Image Technical Services, Inc., Pfizer, Research, Gilead Sciences, AstraZeneca, BeiGene, Therapy, Biogen, GSK plc, Bayer, Bristol-Myers Squibb Co. v. Superior Court, Eli Lilly and Company, Lymphoma, Pharmaceutical industry

This study identifies the research grants and funding as one of the prime reasons driving the non-Hodgkin lymphoma therapeutics market growth during the next few years.

Key Points: 
  • This study identifies the research grants and funding as one of the prime reasons driving the non-Hodgkin lymphoma therapeutics market growth during the next few years.
  • Also, growing awareness about cancer and increase in patient assistance programs and reimbursements will lead to sizable demand in the market.
  • The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

HEXO Wins Complete Dismissal of Putative Québec Shareholder Class Action

Retrieved on: 
Friday, January 27, 2023
Retail, Alternative Medicine, Specialty, Health, Court, Bristol-Myers Squibb Co. v. Superior Court, Plaintiff, Civil code, Superior court, TSX, Disclosure

HEXO Corp (TSX: HEXO; NASDAQ: HEXO) (“HEXO”, or the “Company”), a leading producer of high-quality cannabis products, announced today that it has won a complete dismissal of the putative securities class action lawsuit pending before the Québec Superior Court against the Company and its former Chief Executive Officer, filed on November 19, 2019 on behalf of certain primary market and secondary market purchasers of securities of the Company.

Key Points: 
  • HEXO Corp (TSX: HEXO; NASDAQ: HEXO) (“HEXO”, or the “Company”), a leading producer of high-quality cannabis products, announced today that it has won a complete dismissal of the putative securities class action lawsuit pending before the Québec Superior Court against the Company and its former Chief Executive Officer, filed on November 19, 2019 on behalf of certain primary market and secondary market purchasers of securities of the Company.
  • As previously disclosed, HEXO and its former Chief Executive Officer (“Defendants”) were named in a shareholder class action lawsuit filed in the province of Québec.
  • In a 48-page opinion dated January 23, 2023, the Superior Court of Québec dismissed the Plaintiff’s amended motion in its entirety, with costs.
  • “We’re very satisfied with the Court’s detailed opinion, which dismissed the Plaintiff’s claims and supports HEXO’s position,” said Charlie Bowman, CEO and President of HEXO.

The Global Addison's Disease Therapeutics Market is expected to grow by $442 mn from 2023-2027, accelerating at a CAGR of 6.93% during the forecast period

Retrieved on: 
Wednesday, November 30, 2022
Amgen, Bristol-Myers Squibb Co. v. Superior Court, Abbott Laboratories, Pfizer, Biogen, M. Levin & Co, Inc, Lupin Limited, Bayer, Neurocrine Biosciences, Degenerative disease, Eli Lilly and Company, Novartis, Bio-Techne, GlaxoSmithKline, Research, Therapy, Pharmaceutical industry

View original content:https://www.prnewswire.com/news-releases/the-global-addisons-disease-the...

Key Points: 
  • Also, the availability of clinical guidelines and redefined pathophysiology will lead to sizable demand in the market.
  • The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • Also, Addisons disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

EQS-News: This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

Retrieved on: 
Monday, October 31, 2022
Fatty liver disease, European Medicines Agency, Safety, Prostate, Institute of Liver and Biliary Sciences, TASE, Psoriasis, Liver cancer, Hepatocellular carcinoma, CANF, NYSE American, Food, HCC, Cancer, Liver, Erectile dysfunction, Forward-looking statement, Patient, Risk, AMGN, SEC, NASH, BMY, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Industry, Inflammation, Melanoma, European Academy of Management, EMA, Company, Advertising, NASDAQ, FDA, Population, Drug development, Technology, News, Communication, Arbutus Biopharma, Colon, Heat, COVID-19, Review, Amgen, Journal of the European Academy of Dermatology and Venereology, Bristol-Myers Squibb Co. v. Superior Court, Pharmaceutical industry, Dietary supplement, Dermatology

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.

Key Points: 
  • The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
  • Pharmaceutical companies are racing to develop new proprietary psoriasis pill options.
  • The company reports that Piclidenoson is now advancing into a Phase III psoriasis registration trial.
  • Among its Piclidensoson drug study findings, Can-Fite reported:
    Piclidenoson demonstrated an excellent safety profile, overlapping the placebo-treated group.

EQS-News: Jupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives

Retrieved on: 
Saturday, October 22, 2022
News, Personal lubricant, Sexual desire, Female, American Cancer Society, Woman, Survivor, Research report, Attention, PFE, Breast augmentation, Bristol-Myers Squibb Co. v. Superior Court, NYSE, NASDAQ, Patient, Galena Biopharma, Contract, Research, Man, Pfizer, Breast, International Agency for Research on Cancer, Hair loss, Sensation, Burns, History, Merck, Technology, Eye, Manifest and latent functions and dysfunctions, Lung cancer, Human, Health, BMY, US, Libido, Health minister, Breast cancer, Safety, Sexual arousal, OTC, Advertising, Organic, Skin, Intellectual property, Dermatitis, Ageing, MRK, Male, Dietary supplement, Medical imaging, Birth control, Pharmaceutical industry, Cancer

In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S.

Key Points: 
  • In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S.
  • Breast cancer affects men, too, and about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022 with a mans lifetime risk of breast cancer being about 1 in 833.
  • About 85% of breast cancers occur in women who have no family history of breast cancer.
  • Yet the adverse effects of cancer treatment continue to cause concern and unhappiness for breast cancer survivors.

Global Gallbladder Cancer Therapeutics Markets, 2022-2026 - Rising Adoption of Immunotherapy and Next-Generation Sequencing (NGS)-Based Testing will Lead to Sizable Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 28, 2022
Health, Oncology, Sun Pharma, Novartis, NGS, Therapy, Bristol-Myers Squibb Co. v. Superior Court, Sanofi, CAGR, Lists of countries and territories, Adoption, Incidence, Risk, Eli Lilly and Company, Immunotherapy, Industry, Gallbladder cancer, Pharmaceutical industry

The gallbladder cancer therapeutics market is poised to grow by $103.57 million during 2022-2026, accelerating at a CAGR of 5.44%

Key Points: 
  • The gallbladder cancer therapeutics market is poised to grow by $103.57 million during 2022-2026, accelerating at a CAGR of 5.44%
    The market is driven by strong incidence of gallbladder cancer in developing countries, rising risk factors for gallbladder cancer, and advent of targeted therapy.
  • This study identifies the strong pipeline as one of the prime reasons driving the gallbladder cancer therapeutics market growth during the next few years.
  • Also, rising adoption of immunotherapy and next-generation sequencing (NGS)-based testing will lead to sizable demand in the market.
  • The gallbladder cancer therapeutics market analysis includes the type segment and geographic landscape.

Global Hepatitis B Therapeutics Markets, 2022-2026: A Strong Pipeline and Increasing Awareness and Screening Programs of HBV Diagnostic Tests will Lead to Sizable Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Pharmaceutical, HBV, Emergent, Awareness, Hepatitis, Viatris, Bristol-Myers Squibb Co. v. Superior Court, Novartis, Prevalence, Merck, GlaxoSmithKline, Therapy, A.D. Bedell Wholesale Co., Inc. v. Philip Morris Inc., Emergent BioSolutions, Gilead Sciences, Hepatitis B, Vaccine, Pharmaceutical industry

The market is driven by the increasing prevalence of hepatitis B in infants, growing initiatives to increase awareness about hepatitis B, and growing demand for molecular diagnostics of HBV.

Key Points: 
  • The market is driven by the increasing prevalence of hepatitis B in infants, growing initiatives to increase awareness about hepatitis B, and growing demand for molecular diagnostics of HBV.
  • This study identifies the new technological advancements as one of the prime reasons driving the hepatitis b therapeutics market growth during the next few years.
  • Also, a strong pipeline, and increasing awareness and screening programs of HBV diagnostic tests will lead to sizable demand in the market.
  • The hepatitis b therapeutics market analysis includes application segment and geographic landscape.